Haloperidol disrupts lipid rafts and impairs insulin signaling in SH-SY5Y cells

Neuroscience

Volumn 167, Issue 1, 2010, Pages 143-153

  Sanchez Wandelmer J ^a   Davalos A ^a   de la Pena G ^a   Cano, S ^a   Giera, M ^b   Canfran Duque A ^a   Bracher, F ^b   Martin Hidalgo A ^a,c   Fernandez Hernando C ^a   Lasuncion M A ^a,c,d   Busto, R ^a,c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Antipsychotic drug; Cholesterol biosynthesis; Haloperidol; Insulin; Lipid rafts; Signal transduction

Indexed keywords

7 DEHYDROCHOLESTEROL; CHOLESTA 8,14 DIEN 3BETA OL; CHOLESTEROL; DELTA7 REDUCTASE; FLOTILLIN 1; HALOPERIDOL; INSULIN; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDOREDUCTASE; PROTEIN KINASE B; PROTEIN KINASE FYN; STEROID REDUCTASE; STEROL; UNCLASSIFIED DRUG; ZYMOSTENOL;

ARTICLE; CELL LEVEL; CELL LINE; CELL MEMBRANE; CELL STRAIN HL 60; CELLULAR DISTRIBUTION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTERNALIZATION; LIPID COMPOSITION; LIPID RAFT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SH SY5Y CELL; SIGNAL TRANSDUCTION;

CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CHOLESTEROL; CHOLESTEROL, LDL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; INSULIN; MEMBRANE MICRODOMAINS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-FYN; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; STEROLS;

EID: 77950367439     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.01.051     Document Type: Article

References (54)

1. Alimohamad H., Rajakumar N., Seah Y.H., Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005, 57:533-542.
2. Bickel P.E. Lipid rafts and insulin signaling. Am J Physiol Endocrinol Metab 2002, 282:E1-E10.
3. Bobes J., Rejas J., Garcia-Garcia M., Rico-Villademoros F., García-Portilla M.P., Fernández I., Hernández G. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003, 62:77-88. EIRE Study Group.
4. Brown A.J., Sun L., Feramisco J.D., Brown M.S., Goldstein J.L. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol Cell 2002, 10:237-245.
5. Brusselmans K., Timmermans L., Van de Sande T., Van Veldhoven P.P., Guan G., Shechter I., Claessens F., Verhoeven G., Swinnen J.V. Squalene synthase, a determinant of raft-associated cholesterol and modulator of cancer cell proliferation. J Biol Chem 2007, 282:18777-18785.
6. Calvo D., Gomez-Coronado D., Suarez Y., Lasuncion M.A., Vega M.A. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res 1998, 39:777-788.
7. Chattopadhyay A., Paila Y.D. Lipid-protein interactions, regulation and dysfunction of brain cholesterol. Biochem Biophys Res Commun 2007, 354:627-633.
8. Dai Y., Wei Z., Sephton C.F., Zhang D., Anderson D.H., Mousseau D.D. Haloperidol induces the nuclear translocation of phosphatidylinositol 3'-kinase to disrupt Akt phosphorylation in PC12 cells. J Psychiatry Neurosci 2007, 32:323-330.
9. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004, 36:131-137.
10. Fernandez C., Martin M., Gomez-Coronado D., Lasuncion M.A. Effects of distal cholesterol biosynthesis inhibitors on cell proliferation and cell cycle progression. J Lipid Res 2005, 46:920-929.
11. Ferno J., Raeder M.B., Vik-Mo A.O., Skrede S., Glambek M., Tronstad K.J., Breilid H., Lovlie R., Berge R.K., Stansberg C., Steen V.M. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J 2005, 5:298-304.
12. Ferno J., Skrede S., Vik-Mo A.O., Havik B., Steen V.M. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006, 7:69.
13. Gielen E., Baron W., Vandeven M., Steels P., Hoekstra D., Ameloot M. Rafts in oligodendrocytes: evidence and structure-function relationship. Glia 2006, 54:499-512.
14. Giera M., Plossl F., Bracher F. Fast and easy in vitro screening assay for cholesterol biosynthesis inhibitors in the post-squalene pathway. Steroids 2007, 72:633-642.
15. Girgis R.R., Javitch J.A., Lieberman J.A. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008, 13:918-929.
16. Hashimoto K., Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006, 12:3857-3876.
17. Havrankova J., Schmechel D., Roth J., Brownstein M. Identification of insulin in rat brain. Proc Natl Acad Sci U S A 1978, 75:5737-5741.
18. Kelley R.I., Hennekam R.C. The Smith-Lemli-Opitz syndrome. J Med Genet 2000, 37:321-335.
19. Kirsch C., Eckert G.P., Mueller W.E. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 2003, 65:843-856.
20. Korade Z., Kenworthy A.K. Lipid rafts, cholesterol, and the brain. Neuropharmacology 2008, 55:1265-1273.
21. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zochling R., Boissl K.W., Leblhuber F., Riederer P. Persistence of haloperidol in human brain tissue. Am J Psychiatry 1999, 156:885-890.
22. Korpi E.R., Kleinman J.E., Costakos D.T., Linnoila M., Wyatt R.J. Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 1984, 11:259-269.
23. Lange Y., Ye J., Steck T.L. Circulation of cholesterol between lysosomes and the plasma membrane. J Biol Chem 1998, 273:18915-18922.
24. Liu L., Brown D., McKee M., Lebrasseur N.K., Yang D., Albrecht K.H., Ravid K., Pilch P.F. Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab 2008, 8:310-317.
25. Lu X., Kambe F., Cao X., Yoshida T., Ohmori S., Murakami K., Kaji T., Ishii T., Zadworny D., Seo H. DHCR24-knockout embryonic fibroblasts are susceptible to serum withdrawal-induced apoptosis because of dysfunction of caveolae and insulin-Akt-Bad signaling. Endocrinology 2006, 147:3123-3132.
26. Martinez-Botas J., Ferruelo A.J., Suarez Y., Fernandez C., Gomez-Coronado D., Lasuncion M.A. Dose-dependent effects of lovastatin on cell cycle progression. Distinct requirement of cholesterol and non-sterol mevalonate derivatives. Biochim Biophys Acta 2001, 1532:185-194.
27. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
28. Murata T., Maruoka N., Omata N., Takashima Y., Igarashi K., Kasuya F., Fujibayashi Y., Wada Y. Effects of haloperidol and its pyridinium metabolite on plasma membrane permeability and fluidity in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:848-857.
29. Paila Y.D., Murty M.R., Vairamani M., Chattopadhyay A. Signaling by the human serotonin (1A) receptor is impaired in cellular model of Smith-Lemli-Opitz syndrome. Biochim Biophys Acta 2008, 1778:1508-1516.
30. Parpal S., Karlsson M., Thorn H., Stralfors P. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J Biol Chem 2001, 276:9670-9678.
31. Perez-Iglesias R., Mata I., Pelayo-Teran J.M., Amado J.A., Garcia-Unzueta M.T., Berja A., Martinez-Garcia O., Vazquez-Barquero J.L., Crespo-Facorro B. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res 2009, 107:115-121.
32. Pike L.J. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 2005, 1746:260-273.
33. Plum L., Schubert M., Bruning J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 2005, 16:59-65.
34. Rahier A., Taton M. Sterol biosynthesis: strong inhibition of maize delta 5,7-sterol delta 7-reductase by novel 6-aza-B-homosteroids and other analogs of a presumptive carbocationic intermediate of the reduction reaction. Biochemistry 1996, 35:7069-7076.
35. Sanchez-Wandelmer J., Davalos A., Herrera E., Giera M., Cano S., de la Pena G., Lasuncion M.A., Busto R. Inhibition of cholesterol biosynthesis disrupts lipid raft/caveolae and affects insulin receptor activation in 3T3-L1 preadipocytes. Biochim Biophys Acta 2009, 1788:1731-1739.
36. Sanchez-Wandelmer J., Hernandez-Pinto A.M., Cano S., Davalos A., de la Pena G., Puebla-Jimenez L., Arilla-Ferreiro E., Lasuncion M.A., Busto R. Effects of the antipsychotic drug haloperidol on the somastostatinergic system in SH-SY5Y neuroblastoma cells. J Neurochem 2009, 110:631-640.
37. Shrivastava S., Paila Y.D., Dutta A., Chattopadhyay A. Differential effects of cholesterol and its immediate biosynthetic precursors on membrane organization. Biochemistry 2008, 47:5668-5677.
38. Silve S., Dupuy P.H., Labit-Lebouteiller C., Kaghad M., Chalon P., Rahier A., Taton M., Lupker J., Shire D., Loison G. Emopamil-binding protein, a mammalian protein that binds a series of structurally diverse neuroprotective agents, exhibits delta8-delta7 sterol isomerase activity in yeast. J Biol Chem 1996, 271:22434-22440.
39. Simpson G.M., Cooper T.B., Braun G.A. Further studies on the effect of butyrophenones on cholesterol synthesis in humans. Curr Ther Res Clin Exp 1967, 9:413-418.
40. Singh P., Paila Y.D., Chattopadhyay A. Differential effects of cholesterol and 7-dehydrocholesterol on the ligand binding activity of the hippocampal serotonin(1A) receptor: implications in SLOS. Biochem Biophys Res Commun 2007, 358:495-499.
41. Song K.S., Li S., Okamoto T., Quilliam L.A., Sargiacomo M., Lisanti M.P. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 1996, 271:9690-9697.
42. Suarez Y., Fernandez C., Gomez-Coronado D., Ferruelo A.J., Davalos A., Martinez-Botas J., Lasuncion M.A. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin. Cardiovasc Res 2004, 64:346-355.
43. Summerly R., Yardley H.J. The effect of a substituted fluorobutyrophenone (haloperidol) on the metabolism of sterols in rat skin. Biochem J 1965, 96:30.
44. Taghibiglou C., Bradley C.A., Gaertner T., Li Y., Wang Y., Wang Y.T. Mechanisms involved in cholesterol-induced neuronal insulin resistance. Neuropharmacology 2009, 57:268-276.
45. Tessier C., Nuss P., Staneva G., Wolf C. Modification of membrane heterogeneity by antipsychotic drugs: an X-ray diffraction comparative study. J Colloid Interface Sci 2008, 320:469-475.
46. Tsui-Pierchala B.A., Encinas M., Milbrandt J., Johnson E.M. Lipid rafts in neuronal signaling and function. Trends Neurosci 2002, 25:412-417.
47. Ukai W., Ozawa H., Tateno M., Hashimoto E., Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 2004, 111:667-681.
48. Vainio S., Heino S., Mansson J.E., Fredman P., Kuismanen E., Vaarala O., Ikonen E. Dynamic association of human insulin receptor with lipid rafts in cells lacking caveolae. EMBO Rep 2002, 3:95-100.
49. Vance J.E., Hayashi H., Karten B. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 2005, 16:193-212.
50. Van der Heide L.P., Ramakers G.M., Smidt M.P. Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol 2006, 79:205-221.
51. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002, 63:856-865.
52. Wu C., Butz S., Ying Y., Anderson R.G. Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane. J Biol Chem 1997, 272:3554-3559.
53. Zhao Z., Ksiezak-Reding H., Riggio S., Haroutunian V., Pasinetti G.M. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 2006, 84:1-14.
54. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., Strakowski S.M., Sharma T., Kahn R.S., Gur R.E., Tollefson G.D., Lieberman J.A. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005, 87:537-543.